Key result
Nonpharmacologic SBP control to <130 mmHg could prevent ~26,100 CVD events in lower-risk stage 1 hypertension.
Why the study?
The nationwide reduction in CVD and healthcare expenditures achievable through nonpharmacologic management in low-risk stage 1 hypertension remained unquantified.
Does nonpharmacologic management of stage 1 hypertension reduce 10-year CVD events and mortality in low-risk US adults?
Does nonpharmacologic management of stage 1 hypertension reduce 10-year CVD events and mortality in low-risk US adults?
Widespread adoption of nonpharmacologic therapies for stage 1 hypertension in low-risk adults could prevent tens of thousands of CVD events and save billions in healthcare costs over a decade.
Answers are grounded in this paper and cite their sources.
May support nonpharmacologic control in low-risk stage 1 hypertension; leaves open confirmation via prospective trials.
Background: The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines newly classified 31 million US adults as having stage 1 hypertension. The ACC/AHA guidelines recommend behavioral change without pharmacology for the low-risk portion of this group. However, the nationwide reduction in cardiovascular disease (CVD) and associated healthcare expenditures achievable by evidence-based dietary improvements, sustained weight loss, adequate physical activity, and alcohol moderation remain unquantified. We estimated the effect of systolic BP (SBP) control and behavioral changes on 10-year CVD outcomes and costs. Methods: defined as untreated SBP 130-139 mmHg and diastolic BP <90 mmHg; no history of CVD, diabetes, or chronic kidney disease; and low 10-year risk of CVD. We used published meta-analyses and trials to estimate the effects of behavior modification on SBP. We assessed the extent to which intermittent healthcare utilization or partial uptake of nonpharmacologic therapy would decrease CVD events prevented. Results: Controlling SBP to <130 mmHg among the estimated 8.8 million U.S. adults (51% women) in the target population could prevent 26,100 CVD events, avoid 2,900 deaths, and save $1.6 billion in healthcare costs over 10 years. The Dietary Approaches to Stop Hypertension (DASH) diet could prevent 16,000 CVD events among men and 12,000 among women over a decade. Other nonpharmacologic interventions could avert between 3,700 and 19,500 CVD events. However, only 5.5 million (61%) of the target population regularly utilized healthcare where recommended clinician counseling could occur. Conclusions: As only two-thirds of U.S. adults with Stage 1 hypertension regularly receive medical care, substantial benefits to cardiovascular health and associated costs may only stem from policies that promote widespread adoption and sustained adherence of nonpharmacologic therapy. Future work should quantify the population-level costs, benefits, and efficacy of improving the food system and local infrastructure on health behavior change.
No takes yet. Share an insight, caveat, or question.
Sims et al. (2023) studied Stage 1 systolic hypertension (n=8,800,000). Nonpharmacologic management (controlling SBP to <130 mmHg) vs. Status quo was evaluated on Incident CVD events prevented (95% CI 22,600-30,700). Controlling systolic blood pressure to <130 mmHg via nonpharmacologic therapy in lower-risk US adults with stage 1 hypertension could prevent 26,100 cardiovascular disease events over 10 years.
Synapse has enriched 10 related papers. Consider them for comparative context: